Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease

Clinical PET studies using 18F-THK5351 have demonstrated significant tracer retention in sites susceptible to tau burden in Alzheimer disease (AD). However, the in vivo PET signal to reflect tau aggregates remains controversial. Methods: We examined the spatial pattern of tracer binding, amyloid-β, tau, and gliosis in an autopsy-confirmed AD patient who underwent 18F-THK5351 and 11C-Pittsburgh compound B PET before death. Results: Regional in vivo 18F-THK5351 retention was significantly correlated with the density of tau aggregates in the neocortex and monoamine oxidase-B in the whole brain, but not correlated with that of insoluble amyloid-β. Furthermore, significant association was observed between the density of tau aggregates, monoamine oxidase-B, and glial fibrillary acidic protein, suggesting that neocortical tau would strongly influence the formation of reactive astrocytes. Conclusion: 18F-THK5351 PET may have limited utility as a biomarker of tau pathology in AD; however, it could be used to monitor the neuroinflammatory processes in the living brain.

[1]  S. Gauthier,et al.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.

[2]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[3]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[4]  Kazuhiko Yanai,et al.  Tau PET Imaging in Alzheimer’s Disease , 2014, Current Neurology and Neuroscience Reports.

[5]  A. Nordberg,et al.  3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain , 2013, Journal of Neuroinflammation.

[6]  Alan A. Wilson,et al.  Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Ove Almkvist,et al.  Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG , 2012, The Journal of Nuclear Medicine.

[8]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[9]  J. Growdon,et al.  Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. , 2011, The American journal of pathology.

[10]  H. Engler,et al.  In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  B. Gulyás,et al.  Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography , 2011, Neurochemistry International.

[12]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[13]  N. Volkow,et al.  Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects , 1997, Neurobiology of Aging.

[14]  V. Chan‐Palay,et al.  Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography , 1994, Neuroscience.

[15]  C. Rowe,et al.  Aβ-amyloid and Tau Imaging in Dementia. , 2017, Seminars in nuclear medicine.